Table 1: Therapeutic applications of bone marrow derived-stem cells in liver cirrhosis patients.
Cell type | Dose | Route | Sample size (n) | Outcome | Reference |
BM | Single median dose/1 × 108 | Hepatic artery | 10 | Increased serum albumin; Decreased bilirubin | [22] |
BM | Single median dose/240-1027 × 106 | Intravenous | 22 | Increased serum albumin; Decreased bilirubin and ascites | [34] |
BM | Single median dose/5.2 × 109 | Peripheral vein | 9 | Increased serum albumin; Decreased CPS | [20] |
BM | Single median dose/0.48-1.48 × 108/kg body weight | Peripheral vein | 10 | Increased serum albumin; Decreased ascites | [11] |
BM | Single median dose/8 × 109 | Peripheral vein | 5 | Increased serum albumin and protein; Decreased prothrombin time | [35] |
BM | Single median unspecified dose | Hepatic artery | 30 | Increased serum albumin; Decreased CPS | [72] |